Showing 51-60 of 84 results for "".
- FDA Grants 510(k) Clearance to Venus the Versa Pro Systemhttps://modernaesthetics.com/news/fda-grants-510k-clearance-to-venus-the-versa-pro-system/2473495/The U.S. Food and Drug Administration has granted marketing clearance to Venus Concept Inc.’s Venus Versa Pro System. Venus Versa is customizable and upgradable and supports 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF tec
- Apyx Medical Corporation Scores FDA 510(k) Clearance for Renuvion Handpiecehttps://modernaesthetics.com/news/apyx-medical-corporation-scores-fda-510k-clearance-for-renuvion-handpiece/2473245/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Laseroptek's PicoLO Scores FDA 510(k) Marketing Clearancehttps://modernaesthetics.com/news/laseropteks-picolo-scores-fda-510k-marketing-clearance/2471951/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the compa
- Dr. Jason Bloom Shares Latest Innovations from Korean Skincare on Philadelphia Newscasthttps://modernaesthetics.com/news/dr-jason-bloom-shares-latest-skincare-innovations-from-korean-skincare/2473702/Korean skincare, also known as K-Beauty, has become increasingly popular in the United States as Americans look to achieve “glass” skin. Social media, particularly TikTok, has played a large role in promoting K-Beauty lines and products. Jason Bloom, MD, is the founder
- Study Explores Improving Neck Laxity, Wrinkle Severityhttps://modernaesthetics.com/news/ma-chief-medical-editor-leads-study-to-improve-neck-laxity-wrinkle-severity/2473621/A new case study published in Cureus by Saami Khalifian, MD; Alec D. McCarthy, MD; and Steven Yoelin, MD, investigates the efficacy and safety of an injectable therapy to treat neck wrinkles and skin laxity by utilizing a combination of hyperdiluted calcium hydroxylapatite (CaHA), platelet-r
- FDA Clears Renuvion APR Handpiece for Coagulation of Subcutaneous Soft Tissues after Liposuction for Body Contouringhttps://modernaesthetics.com/news/fda-clears-renuvion-apr-handpiece-for-coagulation-of-subcutaneous-soft-tissues-after-liposuction-for-body-contouring/2473404/The U.S. Food and Drug Administration (FDA) cleared the Renuvion APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. “The Renuvion APR handpiece is the only device to have a 510(k)
- Sculpture OK'd as Double Chin Treatmenthttps://modernaesthetics.com/news/sculpsure-oked-as-double-chin-treatment/2472190/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- AEON 'Aligned' With FDA for Botox Biosimilarhttps://modernaesthetics.com/news/aeon-aligned-with-fda-for-botox-biosimilar/2473682/AEON Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, announced receipt of the formal minutes from a recent Biosimilar Initial Advisory (BIA) Meeting with the US Food and Drug Administration (FDA) for AB
- Venus Concept Introduces Medical Advisory Board for AI.MEhttps://modernaesthetics.com/news/venus-concept-introduces-medical-advisory-board-for-aime/2473449/The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration (FDA) in December 2022,